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http://www.rbej.com/content/12/1/98RESEARCH Open AccessMetformin induces a prompt decrease in
LH-stimulated testosterone response in women
with PCOS independent of its insulin-sensitizing
effects
Dorothea Kurzthaler1†, Dijana Hadziomerovic-Pekic2†, Ludwig Wildt1 and Beata E Seeber1*Abstract
Background: The use of insulin-sensitizing drugs has been shown to improve both the reproductive and the
metabolic aspects of PCOS. However, the mechanisms by which metformin exerts its effects in PCOS are still not
completely understood. There is growing evidence of a direct effect of metformin on ovarian steroidogenesis,
independent of its effects on insulin sensitivity.
Methods: We evaluated the short-term effects of metformin compared to placebo on basal and LH- stimulated
androgen secretion as well as on hormonal and metabolic parameters in 19 women with PCOS during a four-day
randomized, double-blinded placebo-controlled clinical trial. In a three month follow-up evaluation, we investigated
the longer-term therapeutic effects of metformin on ovulation, metabolic and endocrine parameters.
Results: Compared to placebo, 2 days of metformin was associated with a borderline significant reduction in the
free androgen index (FAI) (p = 0.05) and with a reduction in the serum concentration of LH-stimulated testosterone (T)
(p = 0.03). Following three months of use, a decline in serum T was observed, independent of changes in weight,
metabolic parameters, or insulin sensitivity.
Conclusions: In women with PCOS, Metformin induces a prompt decrease in LH-stimulated T secretion after only
several days of use. This action precedes the medication’s effects on insulin sensitivity or weight loss.
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Polycystic ovary syndrome (PCOS) is characterized by ele-
vated circulating androgen levels and/or clinical signs of
hyperandrogenism, chronic oligo- or anovulation and
the presence of polycystic ovaries in ultrasound [1].
Additionally, women with PCOS often have profound
insulin resistance and an alteration in pancreatic β-cell
function [2,3].
The mechanism by which metformin exerts its effects
in PCOS is still not completely clear. Some [4-6], but
not all clinical studies have shown an improvement in* Correspondence: beata.seeber@uki.at
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unless otherwise stated.insulin sensitivity with metformin use [7,8]. In vitro
studies using cultured ovarian cells have demonstrated a
direct metformin-effect on ovarian steroidogenesis [9].
The effects of metformin on adrenal steroidogenesis
have been evaluated in several studies. La Marca et al.
suggested that a one-month course of metformin ther-
apy (1500 mg/day) reduces plasma concentrations of
free testosterone and the adrenal steroidogenic response
to ACTH [10]. However, a study using 1000 mg/d for a
longer period of 12 weeks did not corroborate these
findings [11].
Studies have shown that women with PCOS exhibit in-
creased expression of cytochrome P450c17α (CYP 17),
which results in increased activity of 17α-hydroxylase
and 17,20-lyase in ovarian theca cells [12,13]. This dys-
regulation of CYP 17 enhances the production of 17α-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In cultured theca cells from women with PCOS, insulin
significantly increased the production of androstenedione
after luteinizing hormone (LH) stimulation [14]. Clinically,
decreases in ovarian cytochrome P450c17α activity and
serum free T have been shown following metformin ther-
apy, thought to be secondary to a reduction in insulin se-
cretion [15].
However, it has likewise been shown that insulin-
sensitizing agents used for the treatment of PCOS exhibit
insulin-independent ovarian effects [16]. For example, the
thiazolidinediones directly inhibit ovarian androgen pro-
duction in human ovarian cells in the absence of insulin
[17]. Most previously published studies reporting im-
provement in hyperandrogenemia have evaluated andro-
gen levels in PCOS women following 8 to 12 weeks of
metformin therapy [4,7], though some have observed a re-
duction in testosterone within 1 week of commencing
treatment [18]. Few studies have tested insulin sensitivity
dynamically with an oral glucose tolerance test performed
pre- and post-treatment, making it difficult to delineate
whether improvements in hyperandrogenemia were a dir-
ect effect of metformin or a secondary effect due to de-
creased insulin concentrations.
The primary aim of this study was to test the hypoth-
esis that metformin may temper the typical hyperandro-
genic ovarian response seen in PCOS by a direct effect
on the enzymatic system of the ovary, independent of its
action of improving insulin sensitivity in women with
PCOS. The secondary aim of the study was to determine
the longer-term effects of metformin on weight, men-
strual cyclicity, metabolic and endocrine parameters fol-
lowing a twelve week course of treatment.
Methods
Study design and subjects
The study protocol was approved by the Ethics Com-
mittee of the Innsbruck Medical University and written
informed consent was obtained from all participants.
The study was registered with the European Union
Drug Regulating Authorities Clinical Trials (EudraCT)
with the identifier EudraCT 2006-001911-31.
This was a randomized, double-blinded, placebo-
controlled clinical trial performed over four days and
followed by a twelve week follow-up period. The primary
outcome was short-term change in androgen levels and
stimulated androgen response to LH following 2 days of
medication use. Secondary outcomes included changes in
anthropometric measures, insulin sensitivity, ovulation
rate, menstrual frequency, and metabolic and endocrine
parameters during the twelve week follow-up period.
Women with PCOS were recruited from the Depart-
ment of Gynecological Endocrinology and Reproductive
Medicine of the Innsbruck Medical University (Innsbruck,Austria). To be eligible for the study, subjects had to be
between 18 and 40 years of age and have PCOS, as de-
fined by the Rotterdam consensus criteria [1]. Namely,
the women had to have at least two out of three of the
following: (1) menstrual disorders defined as oligomenor-
rhea (cycle length > 35 d) or amenorrhea (cycle length >
12 weeks), (2) clinical hyperandrogenism (modified
Ferriman-Gallwey score of ≥ 6, presence of acne or sebor-
rhea) and/or biochemical evidence of hyperandrogenemia
(T > 0.4 ng/ml, an established and validated cut-off at our
university), and/or (3) polycystic ovaries by ultrasound.
Exclusion criteria included: diabetes mellitus, hyperpro-
lactinemia, thyroid disorders, late-onset congenital adrenal
hyperplasia, Cushing’s syndrome and liver or kidney dis-
eases, current pregnancy, history of lactic acidosis, and the
use of medications such as insulin sensitizers, insulin, anti-
epileptics, H2-blockers, cholesterol-lowering drugs and di-
uretics. As such, all participants underwent a hormonal
profile, an oral glucose tolerance test and an ACTH-
stimulation test to exclude secondary causes of hyperan-
drogenism and manifest diabetes.
None of the participants had taken hormonal contra-
ceptives, medications that affect gastrointestinal motility
or carbohydrate metabolism for at least 2 months prior
to study begin.
Study protocol
We recorded the results of a routinely performed 75 g oral
glucose tolerance test with glucose and insulin levels mea-
sured at time 0 (fasting, before the glucose load), and
every 15 minutes over a total time of 3 hours. This test
was performed in all participants within the previous
30 days prior to beginning the study.
The study was undertaken in the early follicular phase
following spontaneous or progesterone-induced men-
struation (cycle day 3–5). On study day 1, all women
underwent clinical assessment (age, weight, height, BMI,
blood pressure) and peripheral venipuncture to assess
serum hormonal concentrations of estradiol (E2), Pro-
gesterone (P), FSH, and LH to confirm cycle phase.
Immediately following the baseline assessment, an LH
stimulation test was performed with a load of 75 I.E. re-
combinant human LH (Lutropin alfa, Luveris®, Merck
Serono, Aubonne, Switzerland) by subcutaneous ad-
ministration. Venous blood samples were collected at
time −15, 0, 15, 30, 45 and 60 minutes prior to and
after LH administration. The concentrations of the fol-
lowing hormones were measured before LH administra-
tion and repeated at each time point of assessment during
the LH stimulation test: estradiol (E2), SHBG, T, free T,
dehydroepiandrosterone sulphate (DHEAS), Androstene-
dione (A), and 17 α hydroxyprogesterone (17α-OHP).
Ten women were randomly assigned to receive metfor-
min 500 mg, three times daily and nine women to receive
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Randomization was accomplished by using a random
number table. Metformin and placebo were provided
by Kolassa & Merz GmBH (Vienna, Austria) in num-
bered identical blister packs of six tablets. The subjects
were instructed to take one tablet in the morning, mid-
day and evening after a meal and not to alter their
usual eating habits, physical activity, or lifestyle during
the study. A copy of the randomization code was stored
in a sealed envelope in the patient’s health record for
emergency situations. The randomization code was not
broken until the last patient completed all observations.
Subjects and investigators were blinded to the treat-
ment allocation throughout the study.
The subjects returned on day 4 and the LH-stimulation
test was repeated, as described above.
All study participants were then given metformin
500 mg twice daily for 1 week, followed by 500 mg three
times daily to complete twelve weeks of therapy. Patients
were advised to use barrier contraception if fertility was
not desired and were carefully instructed to stop taking
the drug immediately on confirmation of pregnancy. Dur-
ing this follow-up period, each subject returned for weekly
clinical assessment including anthropometric measures,
evaluation of serum progesterone (level > 5 μg/l confirmed
ovulation), and documentation of menstrual bleeding. Re-
peat hormonal evaluation was performed on cycle day 2
through 7 following a spontaneous menstrual bleed, every
4 to 5 weeks in the absence of menstrual bleeding, and in
all women after 12 weeks of metformin use (at the conclu-
sion of the study). After twelve weeks of metformin use,
the 3-hour 75 g oral glucose tolerance test with every
15 minute blood assessments for glucose and insulin was
repeated, as described above.
Adverse events were recorded throughout the study by
direct questioning and by subject self-report.Laboratory measures and assays
BMI was calculated using the formula BMI = kg/m2.
Glucose was measured with the GOD-PAP-method
(glucose oxidase) with a Roche/Hitachi 904 or 917
analyzer. Intra assay-coefficient of variation (CV) was
0.9%, inter assay CV 1.8%. Insulin was measured using
the ECLIA method with a Coat-A-Count Insulin In-
vitro Diagnostic Test Kit (Diagnostic Products Corpor-
ation, USA). The intra assay CV was 1.9%, inter assay
CV 2.6%. Crossreactivity with proinsulin was reported
as 0.05%.
LH, FSH, E2, DHEAS, SHBG, A, and 17-OHP concen-
trations were measured with electrochemiluminescence
(ECLIA) using commercially available kits (Diagnostic
Products Corporation, USA) and analyzed in a Siemens
Immulite 2000 Immunoassay system.T and fT were measured using a radioimmunoassay
(RIA) method with a Coat-a-count In- vitro Diagnostic
test Kit (Diagnostic Products corporation, USA) in a Sie-
mens Immulite 2000 Immunoassay system. The sensitiv-
ity of theses assays were 0.04 μg/L and 0.015 ng/dL,
respectively. The intra-assay and inter-assay CV for the
range of values pertinent to our patients was less than
10%.
The Free Androgen Index (FAI) was calculated as
follows: FAI = total testosterone (nmol/l) × 100/
SHBG (nmol/l).
The serial values obtained during the 3-h OGTT were
used to calculate the area under the curve (AUC) for both
insulin and glucose, using the trapezoidal method, as pre-
viously described [19]. IR was defined with an AUC of In-
sulin exceeding 12,000, as previously described [20]. In a
similar fashion, an AUC response over 60 minutes was
calculated for each of the serially measured hormones
concentrations following LH stimulation.
Statistical analyses
Descriptive statistics were used for continuous data
obtained at each visit. The results are presented as
means ± SEM, unless otherwise indicated.
Differences between groups were evaluated using non-
parametric tests including the Mann–Whitney U-Test.
Within-group differences and repeated measures were
evaluated using the paired t-test, Wilcoxon-Test and the
Friedman Test.
Data analysis was performed using SPSS 18.0 for Win-
dows (Chicago, IL). P < 0.05 was considered statistically
significant.
Sample size was calculated for a within-group treat-
ment effect. Specifically, expecting a decline in T from a
mean of 0.6 μg/L to 0.4 μg/L (upper limit of normal in
our laboratory) after the 2 days of Metformin and setting
an alpha of 0–05, Power (1-Beta) of 0.80, we needed 10
subjects in the treatment arm.
Results
At the start of the study, all subjects were in the early
follicular phase of the cycle, as confirmed by the meas-
urement of FSH, LH, E2 and P at baseline. The baseline
anthropometric, metabolic, and hormonal characteris-
tics of the metformin and placebo groups are shown in
Table 1.
At baseline, insulin resistance, defined as an area
under the curve of insulin greater than 12,000 μUI/ml ×
180 min on the oral glucose tolerance test, was seen in 8
of the 19 subjects, 3 out of 10 of those who subsequently
received Metformin and 5 out of 9 of those in the pla-
cebo group.
The differences in the baseline (pre-LH administration)
hormone concentrations of E, SHBG, T, free T, DHEAS,
Table 1 Baseline characteristics of the study groups
Metformin Placebo
No. of subjects 10 9
Age (yrs) 26.10 ± 4.25 27.89 ± 4.83
Weight (kg) 78.97 ± 21,86 95.26 ± 21.64
BMI (kg/m2) 29.90 ± 7.41 32.15 ± 6.10
No. with oligomenorrhea (%) 10 (100%) 8 (89%)
No. with PCO on ultrasound (%) 8 (80%) 7 (78%)
Total testosterone (μg/l) 0.58 ± 0.24 0.66 ± 0.36
SHBG (nmol/l) 35.60 ± 24.09 39.02 ± 33.30
Free testosterone (pg/ml) 1.77 ± 0.99 1.92 ± 0.91
Androstendione (μg/l) 3.65 ± 1.47 3.61 ± 0.91
17-OHP (μg/l) 1.35 ± 0.37 1.22 ± 0.49
Free androgen Index 7.78 ± 4.96 7.92 ± 3.26
Estradiol (ng/l) 36.56 ± 14.06 48.00 ± 20.77
DHEAS (mg/l) 2.50 ± 0.97 1.84 ± 0.79
Fasting glucose (mg/dl) 81.80 ± 6.03 86.89 ± 6.57
AUC glucose 18409.70 ± 2059.30 17987.67 ± 2264.72
(mg/dl x 180 min)
Fasting insulin (μIU/ml) 11.06 ± 6.38 18.04 ± 10.66
AUC insulin 12754.40 ± 8060.54 16671 ± 12663.37
(μUI/ml x 180 min)
No. with IR* (%) 3 (30%) 5 (56%)
Data are given as mean ± SEM unless otherwise noted.
*IR was defined as AUC insulin > 12,000 μUI/ml x 180 min.
Table 2 Change (Δ) in hormone parameters from study day 1
treatment
Static parameters Metformin p
Within group
Δ T (ug/l) −0.071 ± 0.147 0.16
Δ SHBG (nmol/l) −1.430 ± 7.456 0.56
Δ FAI −0.640 ± 2,187 0.93
Δ DHEAS (mg/l) 0.153 ± 0.385 0.24
Δ A (μg/l) 0.00 ± 0.158 0.35
Δ 17-OHP (μg/l) 0.490 ± 0.872 0.59
Δ Free T (pg/ml) 0.00 ± 0.158 1.0
Δ E2 (ng/l) 4.899 ± 4.942 0.35
Dynamic parameters
Δ AUC Testosterone −8.100 ± 2.188 0.005
Δ AUC SHBG −112.725 ± 143.358 0.45
Δ AUC DHEAS 10,501 ± 26,467 0.24
Δ AUC A −25.275 ± 13.524 0.09
Δ AUC 17-OHP 1.568 ± 4.698 0.75
Δ AUC Free T −26.325 ± 8.058 0.01
Δ AUC E2 273.214 ± 374.027 0.49
Statistically significant differences are shown in boldface.
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following Metformin or placebo treatment. These re-
sults are shown in Table 2 under Static Parameters.
There was no change of any of these hormones from
day 1 to day 4 within each study group and likewise no
difference between study groups.
We then evaluated the dynamics of these hormones fol-
lowing LH-administration before and following metfor-
min or placebo administration. We again calculated both
within- as well as between-group differences. As shown in
Table 2, under Dynamic Parameters, there was a significant
decrease in the stimulated AUC of T as well as stimulated
AUC of free T within the Metformin group only. On be-
tween group evaluations, only the difference in the AUC of
T statistically differed between the two groups. Namely, fol-
lowing LH-administration, women who received two days
of Metformin treatment showed on average a 8.100 ± 2.188
ug*75 min/l lower AUC T following LH administration,
compared to an average rise of 4.524 ± 4.69 ug*75 min/l in
the AUC T in women receiving placebo (p = 0.02). In both
groups, the LH-stimulated AUC SHBG declined following
2 days of Metformin treatment; in the placebo group, this
decline was statistically significant. Nonetheless, there was
no difference in the response of SHBG to LH-stimulation
between the two groups. With a decline in SHBG, we
would expect a rise in T, which was slight and not statisti-
cally significant in the control group. On the other hand,
the substantial decline in AUC T in the Metformin groupto day 4, following 2 days of Metformin or placebo
Placebo p p
Within group Between group
0.109 ± 0.306 0.32 0.13
−3.056 ± 5.787 0.15 0.61
2.311 ± 3.742 0.10 0.05
−0.004 ± 0.240 0.96 0.31
−0.278 ± 0.151 0.97 0.22
−0.106 ± 0.114 0.38 0.30
−0.278 ± 0.151 0.10 0.22
−2.429 ± 4.117 0.58 0.27
4.524 ± 4.69 0.36 0.02
−320.333 ± 119.331 0.028 0.11
1,508 ± 21,924 0.84 0.45
−3.083 ± 16.652 0.86 0.45
−8.449 ± 6.412 0.22 0.40
−18.167 ± 9.014 0.08 0.45
−247.500 ± 288.740 0.42 0.46
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decline in AUC SHBG.Follow-up period
All 19 women agreed to take 1500 mg daily of Metfor-
min in the open-label follow period of the study. One
patient became pregnant in the second month of the
follow-up period, dropped out of the study, and was thus
excluded from further analyses.
During the 12 weeks of Metformin treatment in the 18
women, we were able to document 9 ovulatory cycles
(serum Progesterone >5 μg/l) in the first 4 weeks, and 8
ovulatory cycles in each of the following 4-week time
intervals.
There was no statistically significant change in weight or
BMI after the 12 weeks of follow-up. We were able to re-
peat the 3 hour oral GTTat the conclusion of the 12 weeks
of metformin in 16 of the study participants. There was
no change from baseline in fasting insulin or fasting glu-
cose, nor in the calculated AUC glucose and AUC insulin
following as part of the OGTT. Likewise, no change in the
measured metabolic parameters (total Cholesterol, LDL,
HDL, triglycerides) was observed from baseline to follow-
ing the 12 weeks of metformin administration.
We compared hormone parameters at the start of the
study to those at the completion of the study, after
12 weeks of metformin treatment. There was a statistically
significant decrease in mean T from 0.63 ± 0.71 μg/l to
0.44 ± 0.45 μg/l, (p = 0.038) and a slight rise in mean
DHEAS from 2.23 ± 0.22 mg/l to 2.55 ± 0.28 mg/l
(p = 0.029). No change in SHBG, free T, or FAI was seen.
We relied on patient self-report for medication com-
pliance, with all women reporting consistent use at the
regular study visits. Side effects were limited to gastro-
intestinal complaints (nausea, diarrhea), reported by 4
women but none of these women discontinued the
medication due to these side effects.Discussion
In this randomized controlled study, we found that a
short, 2-day course of metformin attenuated significantly
the LH-induced testosterone concentration in women
with PCOS. SHBG did not increase during this time
period (appeared in fact to decline) which excludes the
possibility that the T effect was secondary to changes in
SHBG.
Our findings therefore suggest that there is a direct
effect of metformin on androgen secretion and/or produc-
tion at the ovarian level, independent of its insulin-
sensitizing effects. These observations are consistent with
those of Mansfield et al. [9], who reported that in vitro
production of androgens by theca cells can be reduced by
the addition of metformin.Previous clinical studies have shown that a beneficial ef-
fect on hyperandrogenism appears as early as within a few
weeks of treatment with metformin, but several months
seem to be required to see the drug’s effects in improving
hyperinsulinemia [21,22]. In the present study, we provide
preliminary evidence that the drug’s effects on decreasing
androgen production may be even prompter than that,
perhaps within as short as a few days.
Although the main aim of this study was to evaluate
the immediate effects of metformin on hormonal and
metabolic parameters, we did treat all (with the excep-
tion of one patient who became pregnant during the
study period) participants with 1500 mg metformin daily
for a total of 12 weeks in an open-label follow-up. We
found no change in body weight and no improvement in
insulin sensitivity following three months of treatment,
as evidenced by the results of the repeated OGTT at
study conclusion. There was likewise no improvement in
metabolic parameters, such as LDL, HDL or triglycerides
following this relatively short course of treatment. None-
theless, mean serum T levels did significantly decrease
over the 3-month period, consistent with similar findings
in a study we previously conducted [23]. The changes in
SHBG levels observed in this study over the initial two
days are difficult to explain. As they do not exhibit the
expected inverse relationship with T levels, they do sup-
port our view of a direct effect of metformin on ovarian
androgen secretion.
Although this was a prospective, randomized double-
blinded controlled trial, the study has a few minor limi-
tations. We did not perform pill counts nor require
diaries to confirm subject compliance with the medica-
tions. We did, however, see the participants on a weekly
basis during the follow-up phase and were reassured
that the women were compliant. Since the majority of
our subjects (15 out of 19) had hyperandrogenemia, we
cannot be certain of the generalizability of our findings
to normo-androgenemic women with PCOS who may
not demonstrate a comparably large change in testos-
terone response following short term metformin ad-
ministration. Although this study included a relatively
small number of subjects, we based our sample size cal-
culation on showing within-group differences with each
subjects acting as her own control.
Conclusions
Our data suggest that the effects of metformin on ovarian
androgen metabolism in women with PCOS do not re-
quire protracted drug exposure and are not secondary to
improvement/normalization in insulin sensitivity. Rather,
our data imply that there may be a direct effect of the drug
at the ovarian level. Thus, the beneficial mechanism of ac-
tion of metformin in improving hyperandrogenemia in
women with PCOS may be more complicated than at first
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clinical studies with larger number of subjects are war-
ranted to evaluate these effects more closely and to test
their therapeutic implications.
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